 |
|
Not in Our Methods, but in Our Ignorance
Arch Gen Psychiatry. 2002;59:279-280.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE COMMERCIAL development of a new drug product, especially one intended
for the treatment of a psychiatric condition, is a costly, time-consuming,
resource-demanding, and financially risky undertaking. Only a small fraction
of "potentially promising" new drug candidates ever make it into phase 1 clinical
trials, and an even smaller proportion gain marketing approval. Moreover,
among the candidates that eventually do reach the market, only a few can be
deemed truly innovative, let alone major therapeutic advances.
Yet despite the considerable time and effort expended in their development
and testing, drug products typically enter the marketplace while much of potential
medical importance still remains to be learned about their effects, both beneficial
and untoward.
Given the circumstances described, it is eminently reasonable to ask
whether something is amiss in the way we do things. Are intrinsic deficiencies
and flaws in our drug development strategies, methods, and practices contributing
to the difficulties . . . [Full Text of this Article]
RELATED ARTICLES
Improving Clinical Trials: American Society of Clinical Psychopharmacology Recommendations
Donald F. Klein, Michael E. Thase, Jean Endicott, Lawrence Adler, Ira Glick, Amir Kalali, Steven Leventer, Jeffrey Mattes, Peter Ross, and Alexander Bystritsky
Arch Gen Psychiatry. 2002;59(3):272-278.
ABSTRACT
| FULL TEXT
Out of the Box
Alan J. Gelenberg
Arch Gen Psychiatry. 2002;59(3):281.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
Dworkin et al.
Neurology 2005;65:S7-S19.
ABSTRACT
| FULL TEXT
|
